| Dr Steven Franklin Freedman, MD | |
|
850 Aquidneck Ave, Unit B9, Middletown, RI 02842-7244 | |
| (401) 849-4448 | |
| (401) 849-6479 |
| Full Name | Dr Steven Franklin Freedman |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 39 Years |
| Location | 850 Aquidneck Ave, Middletown, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912901869 | NPI | - | NPPES |
| 008156 | Other | RI | TUFTS ID NUMBER |
| 7002780 | Medicaid | RI | |
| 004438 | Other | RI | BLUE CHIP ID NUMBER |
| 1000156 | Other | RI | UNITED HEALTH |
| 1050 | Other | RI | NEIGHBORHOOD HEALTH |
| 0000002519 | Other | RI | RI BLUE CROSS ID NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD08156 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear Nose And Throat Medicine And Surgery Group, Llc | 3072684919 | 2 |
News Archive
Donors at a conference Wednesday pledged to provide Haiti with $5.3 billion over the next 18 months to help the country rebuild after the January earthquake, the Wall Street Journal reports (Rhoads/Lauria, 3/31).
In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
Employing cardiovascular disease prevention strategies in mid-life may delay or stop the brain alterations that can lead to dementia later in life, according to a study in the Journal of the American College of Cardiology.
› Verified 7 days ago
| Entity Name | Ear Nose & Throat Medicine And Surgery Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689772287 PECOS PAC ID: 3072684919 Enrollment ID: O20080619000453 |
News Archive
Donors at a conference Wednesday pledged to provide Haiti with $5.3 billion over the next 18 months to help the country rebuild after the January earthquake, the Wall Street Journal reports (Rhoads/Lauria, 3/31).
In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
Employing cardiovascular disease prevention strategies in mid-life may delay or stop the brain alterations that can lead to dementia later in life, according to a study in the Journal of the American College of Cardiology.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Franklin Freedman, MD 850 Aquidneck Ave, Unit B9, Middletown, RI 02842-7244 Ph: (401) 849-4448 | Dr Steven Franklin Freedman, MD 850 Aquidneck Ave, Unit B9, Middletown, RI 02842-7244 Ph: (401) 849-4448 |
News Archive
Donors at a conference Wednesday pledged to provide Haiti with $5.3 billion over the next 18 months to help the country rebuild after the January earthquake, the Wall Street Journal reports (Rhoads/Lauria, 3/31).
In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
Employing cardiovascular disease prevention strategies in mid-life may delay or stop the brain alterations that can lead to dementia later in life, according to a study in the Journal of the American College of Cardiology.
› Verified 7 days ago
Dr. James Michael Dobbin, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 850 Aquidneck Ave, Unit B-9, Middletown, RI 02842 Phone: 401-849-4448 Fax: 401-849-6479 |